Events
The Biopharmaceutical Conference in Europe
June 17-19, 2009
European Hematology Association 14th Congress
June 4-7, 2009, Berlin, Germany
Presentation Details
American Society of Clinical Oncology
Annual Meeting 2009
May 29 - June 2, 2009, Orlando, Florida
Presentation Details
Preliminary Evidence of Clinical Activity in a Phase I Study of CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase (P13K), in Patients with Select Hematologic Malignancies. View Abstract
Date/Time: Saturday May 30, 8:00 AM to 12:00 PM
Session: Developmental Therapeutics: Molecular Therapeutics
Location: Level 2, West Hall C
Abstract: #3543
American Society of Hematology's
50th Annual Meeting
December 6-9, 2008, San Francisco, CA
Oral Presentation
CAL-101, a potent selective inhibitor of the p110d isoform of phosphatidylinositol 3-kinase, attenuates PI3K signaling and inhibits proliferation and survival of Acute Lympoblastic Leukemia in addition to a range of other hematological malignancies
Date/Time: Sunday, December 7, 2008 4:30 PM - 6:00 PM
Session: Acute Lymphocytic Leukemia - Biology and Pathophysiology Session
Location: San Francisco Marriott, Golden Gate Hall
Presenter: Brian Lannutti, Ph.D., Calistoga Pharmaceuticals
Powerpoint Slide Presentation (PDF)
Poster Presentation
CAL-101, a specific inhibitor of the p110d isoform of phosphatidylinositide 3-kinase induces cytotoxicity in multiple myeloma (MM)
Date/Time: Sunday, December 7, 2008 6:00 PM - 8:00 PM
Session: Myeloma - Pathophysiology and Preclinical Studies excluding Therapy
Location: Moscone Center, Hall A
Poster: II-847
Presenter: Hiroshi Ikeda, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper
Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute
Harvard Medical School
Poster Presentation
CAL-101, a selective inhibitor of the p110d isoform of phosphatidylinositol 3-kinase, effectively induces apoptosis in primary chronic lymphocytic leukemia cells providing a novel therapeutic strategy for the treatment of this disease
Date/Time: Monday, December 8, 2008 5:30 PM - 7:30 PM
Session: Chronic Lymphocytic Leukemia - Therapy, Excluding Transplantation
Location: Moscone Center, Hall A
Poster: III-247
Presenter: Sarah E. May, Comprehensive Cancer Center, The Ohio State University
